“We are relocating to Austin because of new business connections and proximity to good medical centers," said Dr. Gad M. Gilad, CEO of Gilad&Gilad. "The move will facilitate marketing of our signature products, AgmaSet and AgmaVet, which are superior for supporting proper nerve functions in humans and animals, respectively. The move will also enable clinical studies aimed at substantiating the effectiveness of novel G-Agmatine-based products in supporting additional bodily functions."
The company will maintain its contract manufacturing location in Southern California.
